Stand Up To Cancer
Organisation
Trials
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Collaborator, Phase 1, Active, not recruiting, 31 people, 19 Aug 2021
Collaborator, Phase 2, Completed, 150 people, 14 Jul 2020
Collaborator, Phase 2, Active, not recruiting, 28 people, 10 Feb 2020
Collaborator, Phase 1, Completed, 19 people, 7 Feb 2020
Collaborator, Phase 2, Terminated, 3 people, 20 Nov 2019
Collaborator, Phase 1/2, Withdrawn, 0 people, 9 Apr 2019
Collaborator, Phase 1, Active, not recruiting, 35 people, 14 Mar 2019
Collaborator, Phase 1/2, Withdrawn, 0 people, 9 Jan 2019
Collaborator, Phase 1/2, Withdrawn, 0 people, 5 Oct 2018
Collaborator, Phase 2, Active, not recruiting, 168 people, 20 Jun 2018
Collaborator, Phase 2, Completed, 34 people, 30 Jan 2018
Collaborator, Phase 1/2, Completed, 17 people, 25 Jan 2018
Collaborator, Phase 1, Completed, 20 people, 12 Jul 2017
Collaborator, Phase 2, Completed, 61 people, 10 May 2017
Collaborator, Phase 1/2, Completed, 11 people, 12 Aug 2016
Collaborator, Phase 1/2, Completed, 18 people, 29 Sept 2015
Collaborator, Phase 1, Completed, 22 people, 29 Jan 2014
Sources: clinicaltrials.gov
Awards made
SU2C GASTRIC CANCER INTERCEPTION DREAM TEAM, Early Detection and Interception of Diffuse and Intestinal Gastric Cancer, DT6374, 2025–2028, 1 Jul 2025
SU2C GASTRIC CANCER INTERCEPTION DREAM TEAM, Early Detection and Interception of Diffuse and Intestinal Gastric Cancer, DT6374, 2025–2028, 1 Jul 2025
SU2C GASTRIC CANCER INTERCEPTION DREAM TEAM, Early Detection and Interception of Diffuse and Intestinal Gastric Cancer, DT6374, 2025–2028, 1 Jul 2025
Columbia University Irving Medical Center
SU2C GASTRIC CANCER INTERCEPTION DREAM TEAM, Early Detection and Interception of Diffuse and Intestinal Gastric Cancer, DT6374, 2025–2028, 1 Jul 2025
University of Maryland, College Park
SU2C GASTRIC CANCER INTERCEPTION DREAM TEAM, Early Detection and Interception of Diffuse and Intestinal Gastric Cancer, DT6374, 2025–2028, 1 Jul 2025
Massachusetts General Hospital
SU2C GASTRIC CANCER INTERCEPTION DREAM TEAM, Early Detection and Interception of Diffuse and Intestinal Gastric Cancer, DT6374, 2025–2028, Lead, 1 Jul 2025
SU2C GASTRIC CANCER INTERCEPTION RESEARCH TEAM, Early Detection and Interception of Diffuse and Intestinal Gastric Cancer, RT6072, 2020–2024, 1 Sept 2020
SU2C GASTRIC CANCER INTERCEPTION RESEARCH TEAM, Early Detection and Interception of Diffuse and Intestinal Gastric Cancer, RT6072, 2020–2024, 1 Sept 2020
SU2C GASTRIC CANCER INTERCEPTION RESEARCH TEAM, Early Detection and Interception of Diffuse and Intestinal Gastric Cancer, RT6072, 2020–2024, 1 Sept 2020
SU2C GASTRIC CANCER INTERCEPTION RESEARCH TEAM, Early Detection and Interception of Diffuse and Intestinal Gastric Cancer, RT6072, 2020–2024, 1 Sept 2020
Massachusetts General Hospital
SU2C GASTRIC CANCER INTERCEPTION RESEARCH TEAM, Early Detection and Interception of Diffuse and Intestinal Gastric Cancer, RT6072, 2020–2024, 1 Sept 2020
City of Hope National Medical Center
SU2C GASTRIC CANCER INTERCEPTION RESEARCH TEAM, Early Detection and Interception of Diffuse and Intestinal Gastric Cancer, RT6072, 2020–2024, 1 Sept 2020
Columbia University Irving Medical Center
SU2C GASTRIC CANCER INTERCEPTION RESEARCH TEAM, Early Detection and Interception of Diffuse and Intestinal Gastric Cancer, RT6072, 2020–2024, 1 Sept 2020
SU2C GASTRIC CANCER INTERCEPTION RESEARCH TEAM, Early Detection and Interception of Diffuse and Intestinal Gastric Cancer, RT6072, 2020–2024, Lead, 1 Sept 2020
Sources: openalex.org